SHOrt course Radiation and TASOX (TAS102 plus oxaliplatin) chemotherapy in operable rectal cancer, a phase II trial. (Virginia Mason IRB CRP18085)


NCT Number:



Study Status:

Closed to Accrual, Study Active





The main purpose of this study is to see if short-course radiation therapy followed by three months of chemotherapy with TAS-102 and oxaliplatin together (known as TASOX) is a safe and effective way to prepare patients for total mesorectal excision (a type of surgery for patients with advanced rectal cancer to remove the tumor and affected areas).

Are you Eligible? (Inclusion Criteria)

  • To be considered for this study, subjects should: -be 18 years of age or older -be newly diagnosed with rectal adenocarcinoma and meet other pathological requirements -have no metastatic disease and meet other clinical requirements -have no chemotherapy within 5 years prior to registration -have no prior radiation to the pelvis

Specialty Area(s)

Principal Investigator

Profile Headshot
  • Chair, Department of Radiation Oncology
  • Associate Director for Cancer Network Strategy in the Herbert Irving Comprehensive Cancer Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032